Biomarkers Market Research Reports & Industry Analysis
The high specificity required of biomarkers in research, drug development and clinical diagnostics creates significant diversity in the global biomarkers market. The greatest focus in biomarkers development is oncology with cancer biomarkers occupying the largest space at over 25% of the market. Biomarkers are parameters or analytes integral to or associated with a biochemical, anatomical, pathogenic, pharmacologic or molecular (genetic) process of clinical interest.
Biomarker discovery continues to power the development of in vitro diagnostic (IVD) tests used to diagnose disease and health conditions, predict patient response to therapy, and monitor therapeutic effects and patient health. Ideal biomarkers have excellent sensitivity and specificity in terms of identifying disease, determining disease state, or evaluating patient response to therapy. Biomarkers are generally proteins (products of gene expression) or nucleic acid sequences (either RNA or DNA); small molecules that are products of metabolism may also serve as biomarkers.
The proliferation of biomarkers is a result of greater clinical understanding of the interconnections between genetics, proteomics and gene expression, disease susceptibility, disease manifestation, and disease susceptibility to select therapies. Biomarkers can be classified as natural history markers (allow for the detection and isolation of a particular cell type), drug activity markers (indicate patient response to pharmological intervention), or surrogate markers (markers that can be used as an alternative to traditional endpoints such as morbidity and mortality to evaluate the effectiveness of a therapy in treating disease). Genomic research is expected to further expand the availability of biomarkers for various diseases and make significant contributions to personalized medicine.
In addition to cancer biomarkers, biomarkers are also available for cardiac function and episodes, other cardiovascular conditions, coagulation or hemostasis, endocrine function, blood sugar management, autoimmune disorders, inflammation, specific infectious diseases, sepsis, and neurological disorders. Over half of the biomarkers market exists in clinical applications, the rest in drug development, research and clinical trial applications. Biomarkers are broadly used for disease risk assessment, diagnosis, screening, treatment or therapy selection, and therapeutic monitoring.